1. Canada Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Vaxil Bio Ltd.

Vaxil Bio Ltd.

0.03
USD
0.00
(0.00%)
0.07EPS
2014 Y
2015 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-4.72
-6.51
-4.33
-5.76
-1.79
-0.61
-0.65
-0.67
-0.36
-0.21
-0.09
-0.06
0.18
0.1
Free Cash Flow per Basic Share
-5.98
-1.43
-2.52
-1.9
-0.99
-0.55
-0.34
-0.62
-0.4
-0.27
-0.2
-0.07
-0.06
-0.07
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
2.73
0.23
-1.44
0.69
-0.48
0.24
-0.33
0.34
0.62
0.41
0.33
0.26
0.34
0.3
Tangible Book Value per Share
2.73
0.23
-1.44
0.69
-0.48
0.24
-0.33
0.34
0.62
0.41
0.33
0.26
0.34
0.3
Basic Weighted Avg Shares
- -
- -
- -
1
1
2
2
2
3
3
3
3
3
4
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
-1
-1
-5
-2
-1
-1
-1
-1
-1
- -
- -
1
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
- -
- -
- -
1
-1
- -
-1
1
2
1
1
1
1
1
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
1
- -
- -
-1
1
2
1
1
1
1
1
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-17.2
-27.06
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
50.17
40.21
Return on Common Equity (%)
-232.78
-528.82
- -
- -
- -
- -
- -
- -
-78.75
-41.18
-25.06
-22.15
50.17
40.21

Capital Structure

CAD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4
4
4
Market Capitalization
1
1
- -

Working Capital

CAD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1
1
1
Cash, Cash Equivalents & STI
1
1
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

CAD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-111.01%
25.54%
90.64%
Free Cash Flow
2.41%
-30.55%
-15.96%
Net Income, GAAP
-29.91%
-109.57%
-393.26%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.02
-0.02
-0.02
-0.01
-0.06
2025
-0.03
0.01
-0.01
0.14
0.18
2026
-0.03
-0.02
- -
- -
- -

Quarterly Dividends Per Share

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Gadi Levin
Full Time Employees
3
Sector
Health technology
Industry
Biotechnology
Address
559 Briar Hill Avenue Toronto ON Canada M5N 1N1
IPO Date
Mar 30, 2010
Website
vaxil-bio.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Vaxil Bio Ltd. (TSXV: VXL) is a Canada-based biotechnology company focused on a novel drug discovery and development platform based on signal peptides (SPs) to target cancer and infectious diseases. The company develops ImMucin, a MUC1 SP-derived vaccine that has completed a Phase I/II clinical trial for multiple myeloma treatment and received orphan drug status from the FDA and EMA; monoclonal antibody candidates including SPmAb2 and SPmAb6 for oncology and infectious diseases; MTbuVax, a tuberculosis vaccine/treatment candidate; and a SP-based COVID-19 vaccine candidate, along with P-Esbp-DOX, a drug delivery polymer targeting E-selectin licensed from BGN Technologies. Founded in 2006 and headquartered in Toronto, Ontario, with operations linked to Rehovot, Israel, Vaxil Bio Ltd. primarily serves the immuno-oncology and infectious disease markets through its proprietary VaxHit bioinformatic platform that identifies universal neoantigens. In August 2024, the company entered a definitive amalgamation agreement with Green Data Centers for a reverse takeover and change of business to data center development, which was subsequently terminated, with Green Data Centers required to repay a related loan by July 2025; it also completed a 1-for-50 reverse stock split effective May 15, 2025, and announced a non-brokered private placement update in November 2025 to explore capital sources for ongoing SP platform advancements.